Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Adverse drug event

EMA reviews safety of blood cancer drug idelalisib

The European Medicines Agency (EMA) has launched a safety review of idelalisib (Zydelig), which is authorised for the treatment of two rare blood cancers, after data from three clinical trials suggest an increased risk of death associated with the drug.

Idelalisib is licensed in the EU to treat chronic lymphocytic leukaemia and follicular lymphoma, a type of non-Hodgkin lymphoma, but new evidence has emerged about the risk of serious adverse events relating to it in combination with other drugs. The increased reports of serious adverse events included deaths, mostly due to infections.

The clinical trials involved patients with chronic lymphocytic leukaemia and indolent non-Hodgkin lymphoma. But the EMA points out that the chronic lymphocytic leukaemia study was looking at combinations of medicines that are currently unapproved, while the non-Hodgkin lymphoma studies included patients with disease characteristics that are different from those covered by the current EMA-approved indications.

The EMA intends to review the data to see if there is any need to change current recommendations. In the meantime, it is advising that patients who are starting treatment with idelalisib should be monitored carefully for signs of infection. Treatment should continue in patients where the drug is well tolerated, the EMA says.

The safety review was requested by the European Commission and is being carried out by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC). Any proposals by the PRAC will be forwarded to the Committee for Medicinal Products for Human Use, which will make a final recommendation to the European Commission.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200873

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.